



Neurotech achieves major milestone with first shipment of Mente Autism devices

- *First shipment of devices to Italy completed*
- *Italian registration of Mente Autism finalised*
- *Initial shipment of devices to be launched in Italy's Campania region*

Perth, Australia & Malta – 22 December 2016 – Developer of quality medical solutions in the neuroscience space, Neurotech International Limited (ASX: NTI), has reached a major company milestone with the first shipment of Mente Autism devices to Italy.

The shipment of 30 devices was completed this week with an initial launch to be conducted in Italy's Campania region.

Delivery of the first Mente Autism units to Italy comes after local product registration was recently completed, the final requirement of Neurotech prior to shipment of the device as part of its Italian distribution agreement. The agreement will see the purchase of a minimum of 8,700 units over the next three years.

Training of the local distributor's sales teams and medical experts has commenced and is ongoing, with various marketing initiatives underway.

"To deliver the first Mente Autism devices to our Italian distribution partner is a pivotal commercial milestone," Neurotech's CEO Wolfgang Storf said.

"We look forward to building on this momentum with increased orders of units flowing to Italy as we move into 2017, as well as the potential for further distribution agreements covering additional geographies."

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420